The most frequent adverse events common to both drugs were anemia, increased ALT and AST and peripheral oedema, with similar incidence except for peripheral oedema, reported at higher rates in the lorlatinib group (56%) compared to the alectinib group (19%). Here, GPT is linked to anemia.